BioCryst Pharmaceuticals Q3 Earnings Call Highlights
Published . Updated .
Key takeaways
- BioCryst Pharmaceuticals (NASDAQ:BCRX) reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a
- Exposed: XLV, XBI, LLY, JNJ, PFE
- Market reaction: XLV +1.9% on the day (still updating); XBI −0.2% on the day (still updating); MRK +2.6% on the day (still updating)
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a
Directly affected
- BCRX Biocryst Pharmaceuticals-7.9% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+22.4% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson-1.7% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+5.5% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+1.9% 18d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| BCRX | -2.67% | -1.63% | base | +0.99% | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | +1.88% | after close | after close | after close |
| XBI | +1.67% | +0.67% | base | -0.23% | after close | after close | after close |
| LLY | -8.42% | +0.54% | base | +0.99% | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | +2.09% | after close | after close | after close |
| PFE | -1.67% | +1.73% | base | +1.60% | after close | after close | after close |
| MRK | -2.47% | +3.37% | base | +2.61% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
BioCryst Pharmaceuticals Q3 Earnings Call Highlights Yahoo Finance
Source: Yahoo Finance
Select Sector Spdr Tr (XLV) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| BCRX | that day | +0.99% | still updating |
| BCRX | three days earlier | -1.63% | final price |
| BCRX | five days earlier | -2.67% | final price |
| Johnson & Johnson (JNJ) | that day | +2.09% | still updating |
| Johnson & Johnson (JNJ) | three days earlier | +2.66% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +1.93% | final price |
| Eli Lilly (LLY) | that day | +0.99% | still updating |
| Eli Lilly (LLY) | three days earlier | +0.54% | final price |
| Eli Lilly (LLY) | five days earlier | -8.42% | final price |
| Merck (MRK) | that day | +2.61% | still updating |
| Merck (MRK) | three days earlier | +3.37% | final price |
| Merck (MRK) | five days earlier | -2.47% | final price |
| Pfizer (PFE) | that day | +1.60% | still updating |
| Pfizer (PFE) | three days earlier | +1.73% | final price |
| Pfizer (PFE) | five days earlier | -1.67% | final price |
| Spdr Series Trust (XBI) | that day | -0.23% | still updating |
| Spdr Series Trust (XBI) | three days earlier | +0.67% | final price |
| Spdr Series Trust (XBI) | five days earlier | +1.67% | final price |
| Select Sector Spdr Tr (XLV) | that day | +1.88% | still updating |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.48% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.31% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 75 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “BioCryst Pharmaceuticals Q3 Earnings Call Highlights”
Companies mentioned with this story
- XLV Select Sector Spdr Tr
In “BioCryst Pharmaceuticals Q3 Earnings Call Highlights,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- XBI Spdr Series Trust
Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “BioCryst Pharmaceuticals Q3 Earnings Call Highlights.” Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
- LLY Eli Lilly
In “BioCryst Pharmaceuticals Q3 Earnings Call Highlights,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- JNJ Johnson & Johnson
For “BioCryst Pharmaceuticals Q3 Earnings Call Highlights,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- PFE Pfizer
In “BioCryst Pharmaceuticals Q3 Earnings Call Highlights,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
- MRK Merck
In “BioCryst Pharmaceuticals Q3 Earnings Call Highlights,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story
How “BioCryst Pharmaceuticals Q3 Earnings Call Highlights” reaches Select Sector Spdr Tr (XLV)
Select Sector Spdr Tr (XLV) is the company in “BioCryst Pharmaceuticals Q3 Earnings Call Highlights,” the 4 Nov 2026 this story story.
What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
Spdr Series Trust (XBI) is here too. Its reason reads: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story
The price range for Select Sector Spdr Tr (XLV), and the dates in the story
LLY traded between 1131.55 and 1447.86 across 20 sessions. The latest close on file is 1409.39.
How solid “BioCryst Pharmaceuticals Q3 Earnings Call Highlights” looks
46 out of 100Price not final
“BioCryst Pharmaceuticals Q3 Earnings Call Highlights” scores 46 out of 100. The score uses 1 sources, and 6 linked companies. The price is not final yet.